<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43529">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01891825</url>
  </required_header>
  <id_info>
    <org_study_id>PAAT</org_study_id>
    <nct_id>NCT01891825</nct_id>
  </id_info>
  <brief_title>Persistent Atrial Fibrillation Ablation Trial</brief_title>
  <acronym>PAAT</acronym>
  <official_title>Persistent Atrial Fibrillation Ablation Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neil Sulke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastbourne General Hospital</source>
  <oversight_info>
    <authority>United Kingdom: National Health Service</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Persistent atrial fibrillation (AF) is a common and distressing condition, that can cause
      significant symptoms. AF ablation is a recognised technique to treat persistent AF, but can
      be technically difficult. This study compares percutaneous ablation to thoracoscopic
      surgical AF ablation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Recurrence of persistent AF by 12 months after ablation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean time to recurrence of persistent AF after ablation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in AF burden after AF ablation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Detected by ILR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first episode of symptomatic AF after ablation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to first episode of symptomatic AF after ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first episode of any AF after ablation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>As detected by ILR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of AF episodes after AF ablation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>As detected by ILR, outside blanking period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of AF episodes lasting greater than 6 minutes after AF ablation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>As detected by ILR, outside blanking period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New MRI-detected subclinical cerebral embolic events</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life changes after AF ablation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in exercise capacity assessed by cardiopulmonary exercise testing (CPET) after AF ablation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in echocardiographic left atrial dimensions and function after AF ablation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in cognitive function as assessed by the Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) instruments</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Pecutaneous AF ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous catheter ablation of atrial fibrillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical AF ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minimally invasive thoracoscopic surgical ablation of atrial fibrillation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical AF ablation</intervention_name>
    <description>Minimally invasive thoracoscopic surgical ablation of atrial fibrillation</description>
    <arm_group_label>Surgical AF ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous AF ablation</intervention_name>
    <description>Percutaneous catheter ablation of atrial fibrillation</description>
    <arm_group_label>Pecutaneous AF ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic persistent or long-standing AF suitable for AF ablation.

          -  Age over 18 years old.

          -  Informed consent to participate in this study.

        Exclusion Criteria:

          -  Pre-existing ILRs or permanent pacemakers that do not allow for continuous monitoring
             for AF occurrence, or are not MRI-safe.

          -  Unable to undergo general anaesthesia for AF ablation.

          -  Previous cardiac surgery, such as coronary artery bypass grafting or valvular
             surgery.

          -  Scheduled for elective cardiac surgery, such as coronary artery bypass grafting or
             valvular surgery.

          -  Previous thoracic surgery.

          -  Participation in a conflicting study.

          -  Potential participants who are mentally incapacitated and cannot consent or comply
             with follow-up

          -  Pregnancy

          -  Other cardiac rhythm disorders
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Sulke, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastbourne General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Conn Sugihara, MBBS</last_name>
    <phone>+44 1323 417400</phone>
    <phone_ext>5869</phone_ext>
    <email>conn.sugihara@esht.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eastbourne General Hospital</name>
      <address>
        <city>Eastbourne</city>
        <state>E Sussex</state>
        <zip>BN21 2UD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Conn Sugihara, MBBS</last_name>
      <phone>01323 417400</phone>
      <phone_ext>5869</phone_ext>
      <email>conn.sugihara@esht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Neil Sulke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steve Furniss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <state>East Sussex</state>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Conn Sugihara, MBBS</last_name>
      <phone>01323 417400</phone>
      <phone_ext>5869</phone_ext>
      <email>conn.sugihara@esht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jonathan Hyde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Lewis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 29, 2013</lastchanged_date>
  <firstreceived_date>June 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Eastbourne General Hospital</investigator_affiliation>
    <investigator_full_name>Neil Sulke</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Persistent atrial fibrillation</keyword>
  <keyword>Atrial fibrillation ablation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
